BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1282 related articles for article (PubMed ID: 26832880)

  • 1. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
    Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
    Gallotta V; Fanfani F; Fagotti A; Chiantera V; Legge F; Gueli Alletti S; Nero C; Margariti AP; Papa V; Alfieri S; Ciccarone F; Scambia G; Ferrandina G
    Ann Surg Oncol; 2014 Jul; 21(7):2369-75. PubMed ID: 24558070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study.
    Ditto A; Martinelli F; Reato C; Kusamura S; Solima E; Fontanelli R; Haeusler E; Raspagliesi F
    Ann Surg Oncol; 2012 Nov; 19(12):3849-55. PubMed ID: 22707110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer.
    Bachmann C; Krämer B; Brucker SY; Stäbler A; Fend F; Wallwiener D; Grischke EM; Rothmund R
    Anticancer Res; 2014 Nov; 34(11):6735-8. PubMed ID: 25368283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
    Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
    Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M; Høgdall CK; Mosgaard BJ
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
    Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of patients with stage IIIC endometrial cancer.
    Turan T; Ureyen I; Duzguner I; Ozkaya E; Tasci T; Karalok A; Boran N; Kose MF; Tulunay G
    Int J Gynecol Cancer; 2014 Jul; 24(6):1033-41. PubMed ID: 24905617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
    Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
    Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer.
    Timmers PJ; Zwinderman K; Coens C; Vergote I; Trimbos JB
    Int J Gynecol Cancer; 2010 Oct; 20(7):1142-7. PubMed ID: 21495216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
    Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
    Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
    Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
    Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
    BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
    Takeshima N; Hirai Y; Umayahara K; Fujiwara K; Takizawa K; Hasumi K
    Gynecol Oncol; 2005 Nov; 99(2):427-31. PubMed ID: 16112718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Metastatic Regional Lymph Node Locations and Predictors of Para-aortic Lymph Node Involvement in Endometrial Cancer Patients at Risk for Lymphatic Dissemination.
    Altay A; Toptas T; Dogan S; Simsek T; Pestereli E
    Int J Gynecol Cancer; 2015 May; 25(4):657-64. PubMed ID: 25647255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.